August 12, 2009
New insight into how human cells reproduce, published by cancer researchers at Michigan State University and the Van Andel Research Institute in Grand Rapids, could help scientists move closer to finding an "off switch" for cancer.
Bayer HealthCare Pharmaceuticals announced today that an orphan drug designation has been granted by the U.S. Food and Drug Administration for ciprofloxacin dry powder inhaler for management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis patients. A similar designation has already been granted by the European Medicines Agency.
bayer, ciprofloxacin, designation, dpi, drug, fda, granted, healthcare, orphan, pharmaceuticals, treatment
Laxai Pharma, Ltd. today announced that it has completed its first acquisition in the clinical research services space by purchasing all of the assets of OSR Solutions, Inc., a New Jersey based contract research organization, for $3.6 million consisting of the following: $1.5mm in cash, $0.75mm in notes, $0.60mm in ...
A research team led by the University of Colorado at Boulder has discovered a previously unknown cellular "switch" that may provide researchers with a new means of triggering programmed cell death, findings with implications for treating cancer.
In his latest Kaiser Health News column, Howard Gleckman writes: "Here's the problem: By the time we need long-term care services we often don't have readily available resources to pay for them.
Congressional Democrats, reportedly closing in on a final health reform agreement, are seeking to alleviate concerns of reluctant members.
Boston Scientific Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved its Express® LD Iliac Premounted Stent System for use in iliac arteries. The Express LD Iliac Stent is the first and only low-profile, premounted, balloon-expandable stent approved by the FDA for use in treating ...
approval, arteries, boston, express, fda, iliac, premounted, receives, scientifics, stent, system
bioMerieux – a world leader in the field of in vitro diagnostics – today announced the launch of the first Food and Drug Administration (FDA) cleared chromID™ VRE, a simple and cost-effective solution in the struggle against vancomycin-resistant enterococci (VRE). chromID VRE is the first to receive an FDA 510(k) ...
